Trial Profile
A 6-Month Open Pilot Study to Investigate the Safety and Tolerability of Immediate Conversion From Calcineurin Inhibitor Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- Acronyms HERMES
- Sponsors Novartis Pharmaceuticals
- 23 Feb 2017 Planned End Date changed from 1 Jun 2009 to 1 Aug 2008.
- 23 Feb 2017 Status changed from suspended to withdrawn prior to enrolment.
- 06 Jan 2011 New trial record